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subgroups, with incremental cost-effectiveness ratios vs. 
vancomycin ranging from €26,900 to €44,500. Hospitali-
zation costs of the first-line treatment of CDI with fidax-
omicin vs. vancomycin were lower in every patient sub-
group, resulting in budget impacts ranging from −€1325 
(in patients ≥65 years) to −€2438 (in cancer patients). 
Reductions in the cost of treating recurrence with fidax-
omicin ranged from −€574.32 per patient in those receiv-
ing concomitant antibiotics to −€1500.68 per patient in 
renally impaired patients.
Conclusions In patient subgroups with CDI at increased 
recurrence risk, fidaxomicin was cost-effective vs. vanco-
mycin, and less costly and more effective in patients with 
cancer.
Keywords Clostridium difficile · Cost-effectiveness · 
Budget impact · Fidaxomicin · Vancomycin
Introduction
Clostridium difficile infection (CDI) is a debilitating con-
dition associated with mortality, substantial morbidity, and 
hospitalization [1, 2]. Treatment options for CDI patients 
have been vancomycin and metronidazole for a number 
of years. However, CDI recurs in approximately 20–25 % 
of patients treated with these agents [3, 4]. Recurrent CDI 
places a heavy burden on patients, including prolonged 
symptoms, repeated courses of antibiotics, and the atten-
dant risk of side-effects and rehospitalization [5]. Certain 
subgroups of patients are more susceptible to recurrence, 
e.g., those with severe CDI, cancer or renal impairment, 
those with a previous recurrence, those aged ≥65 years, and 
those receiving concomitant antibiotics [6–9]. Severe CDI 
and patients with recurrence are recognized as identifiable 
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significant economic healthcare burden, especially the cost 
of recurrent disease. Fidaxomicin produced significantly 
lower recurrence rates and higher sustained cure rates in 
clinical trials. We evaluated the cost-effectiveness and 
budget impact of fidaxomicin compared with vancomycin 
in Germany in the first-line treatment of patient subgroups 
with CDI at increased risk of recurrence.
Methods A semi-Markov model was used to compare 
the cost-effectiveness and budget impact of fidaxomicin 
vs. vancomycin from a payer perspective in Germany. 
The model cycle length was 10 days. The time horizon 
was 1 year. Model inputs were probability of clinical cure, 
30-day probability of recurrence, and 30-day attributable 
mortality based on evidence from two randomized con-
trolled trials comparing fidaxomicin and vancomycin in 
patients with CDI. Cost-effectiveness outcomes were cost 
per quality-adjusted life year gained, cost per bed-day 
saved, and cost per recurrence avoided.
Results Despite higher drug acquisition costs, fidax-
omicin was dominant in the cancer subgroup (less 
costly and more effective) and cost-effective in the other 
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patient subgroups in the real-world clinical setting by ESC-
MID guidelines [10]; elderly patients are at higher risk of 
severe or severe-complicated CDI [11]. Patients with can-
cer, with impaired renal function or receiving concomitant 
antibiotics have been associated with lower cure rates and 
longer time to resolution of diarrhea [7, 12, 13].
CDI also represents a significant economic healthcare 
burden due to the costs associated with increased length 
of hospital stay [14]. Moreover, the costs associated with 
recurrent CDI may be greater than those associated with 
the initial episode, not only as a result of longer hospital 
stay, but also the need for environmental decontamination, 
rigorous hygiene in patient care, and in some cases, cohort 
isolation and ward closure [5]. Indeed, a recent US study 
confirmed a greater healthcare utilization and mortality in 
patients with recurrent CDI compared with non-recurrent 
disease [15]. Moreover, the direct treatment costs of C. 
difficile-associated diarrhea (CDAD) in a German hospi-
tal were recently estimated at €73,898 per patient with ≥1 
recurrence [16]. Clearly, the ability to decrease the risk of 
recurrent CDI is likely to benefit patients, by reducing mor-
bidity and mortality, and also healthcare systems, by reduc-
ing costs.
Fidaxomicin is the first in a new class of macrocyclic 
antibiotics licensed to treat CDI. In two phase III trials, 
fidaxomicin was shown to be non-inferior to vancomycin 
in terms of clinical cure and produced significantly lower 
recurrence rates and significantly higher sustained cure 
rates [3, 17]. In patients with severe CDI and those with 
a first CDI recurrence, recent studies in Scotland and Ire-
land, respectively, have shown that fidaxomicin was cost-
effective compared with vancomycin [18] and less costly 
and more effective than vancomycin or metronidazole [19].
In Europe, the annual management costs of CDI were 
estimated at around €3 billion, and since CDAD occurs 
predominantly among the elderly, this is expected to 
increase in future as the proportion of elderly people in the 
European population increases [20]. In Germany, CDAD 
has been associated with an annual cost burden of €464 
million for the German healthcare system [21]. This study 
evaluates the cost-effectiveness and budget impact of fidax-
omicin compared with vancomycin in Germany in the first-




A semi-Markov model was developed in Microsoft Excel 
to simulate the disease course and therapeutic manage-
ment in patients with CDI. The model evaluated the 
cost-effectiveness and budget impact of fidaxomicin vs. 
vancomycin as the first-line treatment of patient subgroups 
with CDI at increased recurrence risk from a payer perspec-
tive in Germany. The model cycle length was 10 days (cor-
responding to the duration of a course of treatment in clini-
cal practice). The time horizon was 1 year to account for 
multiple recurrences. The base-case model was populated 
with cost data for Germany. No discounting was applied 
to costs or outcomes, because the time horizon was 1 year. 
The model framework was based on information gathered 
from existing clinical guidelines and the available pub-
lished clinical efficacy data for each treatment. The struc-
ture of the model is shown in Fig. 1. It was applied to the 
following patient subgroups, who are more susceptible to 
recurrence [6–9]: patients with ≥1 recurrence; severe CDI; 
those receiving concomitant antibiotics; age ≥65 years; 





Note: An additional state, the death state, is also included in the
economic model. Patients in all of the other health states are at risk
of transitioning to this health state at each model cycle. For the









Fig. 1  Markov model structure used to assess the cost-effectiveness 
of first-line fidaxomicin vs. vancomycin in patients with CDI in Ger-
many.  CDI Clostridium difficile infection
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The cost-effectiveness analysis was evaluated for 
a cohort of 100 patients. Cost-effectiveness outcomes 
were expressed as the cost per quality-adjusted life year 
(QALY) gained, cost per bed-day saved, and the cost per 
recurrence avoided. Irrespective of subgroup, patients 
entered the model in the ‘Initial CDI episode’ state and 
were treated with either fidaxomicin 200 mg twice daily 
or vancomycin 125 mg four times daily for 10 days 
(Treatment 1). Successfully treated patients entered 
and remained in the ‘CDI cured’ health state (Fig. 1). If 
a patient had a recurrence, they then moved back to the 
‘Initial CDI episode’ state and were treated again with 
the initial treatment. If patients did not achieve clini-
cal cure with initial treatment, they received a second 
10-day course of treatment with vancomycin or fidax-
omicin (Treatment 2). If patients were still not cured after 
the second-line therapy, they received third-line ‘rescue’ 
treatment. Patients who were not cured had a risk of CDI-
attributable mortality.
Assumptions
Irrespective of initial treatment, in the base-case, the sec-
ond-line treatment (Treatment 2) for treatment failures 
was vancomycin. ‘Rescue’ treatment (fecal implant) was 
assumed to have a 100 % cure rate, with an assumed cost 
of £1500. This is a representative cost only and does not 
imply that all patients will have this third-line rescue treat-
ment. The third-line rescue treatment is used after two 
treatment failures; only a small percentage of patients over-
all (1.6–2.4 %) go on to receive rescue treatment (Table 12 
Supplementary Data). It was assumed that all cases (initial 
episode, treatment failures, and recurrences) were treated 
in hospital. In addition, the risk of recurrence (all patients) 
and CDI-attributable mortality (non-cured patients only) 




Model inputs were probability of clinical cure, 30-day 
probability of recurrence after the end of treatment, and 
30-day CDI-attributable mortality (Table 1). Clinical cure 
was defined as the resolution of diarrhea with maintenance 
of resolution and no further requirement for CDI therapy 
on the second day after the end of therapy (10 days +2). 
Recurrence was defined as: reappearance of ≥3 diarrheal 
stools per 24-h period within 4 weeks (28 days) after ces-
sation of therapy; the presence of C. difficile toxin A, B, 
or both in the stools; and the need for retreatment for CDI 
following resolution of diarrhea. Model inputs were based 
on data from two phase III clinical trials comparing fidax-
omicin and vancomycin in patients with CDI [3, 9, 12, 17]. 
Recurrence rates for patients with cancer and patients with 
renal impairment were derived from Cornely et al. [12] and 
Mullane et al. [13].
According to the model, clinical cure rates were gen-
erally similar between treatments, although rates were 
slightly higher with fidaxomicin in patients receiving con-
comitant antibiotics and in those with cancer (Table 1). 
Recurrence rates were lower with fidaxomicin (11.4–
20.3 %) than vancomycin (25.5–32.5 %) in all patient sub-
groups. In the model, the same recurrence risk was applied 
to first and subsequent recurrences.
The same mortality rate (6.5 %) was applied to all 
patient subgroups. This was based on 30-day all-cause 
mortality from the comparative phase III trials (6.5 %) [3, 
17] and is based on the assumption that 30-day all-cause 
mortality is a reasonable proxy for CDI-attributable mor-
tality. Indeed, the rate used is consistent with the litera-
ture estimates of CDI-attributable mortality (5.7–6.9 %) 
[22–24].
Safety
No treatment-related adverse events were considered, 
because these were assumed to be mild, based on data 
from clinical trials, and it was assumed that they would 
not lead to additional treatment costs or a switch in 
treatment.
Table 1  Clinical efficacy inputs for the model (pooled data from two 
phase III clinical trials comparing fidaxomicin and vancomycin in 
patients with CDI [3, 9, 12, 17])
CDI Clostridium difficile infection
Fidaxomicin Vancomycin
Clinical cure rate (%)
 ≥1 recurrence 89.8 88.9
 Severe CDI 80.0 82.6
 Concomitant antibiotics 84.3 75.5
 ≥65 years 84.8 84.5
 Cancer 85.1 74.0
 Renal impairment 73.9 76.0
Recurrence rate (%)
 ≥1 recurrence 20.3 32.5
 Severe CDI 11.4 28.3
 Concomitant antibiotics 17.4 25.5
 ≥65 years 16.1 29.3
 Cancer 13.5 29.6
  Renal impairment 14.7 31.6
Mortality rate (%)
 All subgroups 6.5 6.5
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Costs
All costs were expressed in €, for the year 2014. Only 
direct medical costs were considered (the costs of treatment 
with fidaxomicin or vancomycin, and costs of hospitaliza-
tion). The following drug acquisition costs (correct at Q1 
2014) were used [25]:
–– 10-day course of fidaxomicin: €1387.
–– 10-day course of vancomycin: €61.
–– Rescue treatment (fecal implant): €1500 [26].
Hospitalization costs were based on a cost per day of 
€348 on a general ward and an average length of stay of 
14.6 days (derived from the German drug tariff [Institute 
for the Hospital Remuneration System 2014] for DRG 
codes in which a high proportion of cases was listed under 
code A04.7, ‘Enterocolitis due to Clostridium difficile’); 
these include the costs of both materials and personnel. 
In the base-case setting, length of stay was the same for a 
recurrence as for the initial episode.
Utilities
The following health state utility values [27] were used in 
the model: 0.33 per cycle for patients with CDI; 0.56 for 
patients treated successfully (first cycle, 10 days) after the 
end of treatment; 0.78 for successfully treated patients (sec-
ond and subsequent cycles after the end of treatment); and 
0.78 for patients without CDI. Due to a lack of available 
CDI-specific utility data, the data utility source used was 
not disease-specific; however, these utility data have been 
used in other published cost-effectiveness and cost-utility 
CDI models [18, 19].
Sensitivity analyses
One-way deterministic sensitivity analyses were carried 
out to test the robustness of the model outcomes and the 
effect of changing each variable in the model separately. 
Each variable used in the base-case was varied by ±20 %, 
except for the ‘probability of clinical cure’, which is var-
ied by ±10 % to avoid the probability of being greater 
than 100 %. The use of the univariate and best- or worst-
case sensitivity analyses is an important way of identify-
ing parameters that may have a substantial impact on the 
cost-effectiveness results and of explaining the key drivers 
of the model [28]. The cost of rescue treatment and per-
centage of patients receiving rescue treatment were tested 
in sensitivity analyses; since such a small percentage of 
patients receive this therapy, this parameter had very little 
effect on cost-effectiveness outcomes.
Results
Cost‑effectiveness analyses
Despite higher drug acquisition costs, fidaxomicin was 
dominant in the cancer subgroup (less costly and more 
effective) and cost-effective in the other subgroups, with 
incremental cost-effectiveness ratios (ICERs; incremen-
tal cost per QALY gained) vs. vancomycin ranging from 
€26,900 to €44,500 (based on a national willingness-to-
pay threshold of €50,000) [29] (Table 2). Fidaxomicin was 
associated with incremental costs per bed-day saved rang-
ing from €71 to €121 and costs per recurrence avoided 
ranging from €1247 to €2600 (or dominant in the cancer 
subgroup on both measures).
Table 2  Cost-effectiveness results for the first-line treatment of CDI in 100 patients treated with fidaxomicin vs. vancomycin in patient sub-
groups
CDI Clostridium difficile infection, CEA cost-effectiveness analysis, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, 
ICER values are rounded to the nearest 100











≥1 recurrence 46,079 1.05 119 2049 €43,900/QALY 
gained
Cost-effective





29,080 0.95 71 2600 €30,700/QALY 
gained
Cost-effective
≥65 years 46,116 1.04 121 2127 €44,500/QALY 
gained
Cost-effective








Renal impairment 33,403 1.24 73 1,247 €26,900/QALY 
gained
Cost-effective
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Budget impact analyses
The cost per patient derived from the cost-effectiveness 
analysis was used to estimate the budget impact of replac-
ing vancomycin with fidaxomicin in the first-line treatment 
of CDI. The 1-year net budget impact per patient of using 
first-line fidaxomicin rather than vancomycin in each of 
the patient subgroups is shown in Table 3. For each sub-
group, the total cost associated with first-line fidaxomicin 
was higher than vancomycin, with the exception of patients 
with cancer, where the budget impact of fidaxomicin was 
€806 lower per patient. The total costs consist of the cost of 
medication and the cost of hospitalization (Table 4). Hospi-
talization costs of the first-line treatment of CDI with fidax-
omicin vs. vancomycin were lower in every patient sub-
group, resulting in budget impacts ranging from −€1325 
(in patients ≥65 years) to −€2438 (in cancer patients).
Table 5 shows that when patients are treated with fidax-
omicin, although the cost of medication is higher, there 
are considerable savings due to the reduction in recur-
rences, compared with vancomycin in all patient sub-
groups. Reductions in the cost of treating recurrence with 
fidaxomicin ranged from −€574.32 per patient in those 
receiving concomitant antibiotics to −€1500.68 per patient 
in renally impaired patients. Reduction in the number of 
recurrences with fidaxomicin ranged from −0.1118 to 
−0.2678 per patient, respectively.
Sensitivity analyses
The deterministic sensitivity analyses showed that the key 
drivers of cost-effectiveness were the rate of recurrence, 
clinical cure rate, and CDI-attributable mortality rate. 
Details of the sensitivity analyses results are contained in 
the Electronic Supplementary Data online.
Discussion
We developed a semi-Markov decision analytic model to 
assess the cost-effectiveness and budget impact of fidax-
omicin compared with vancomycin as the first-line treat-
ment of patient subgroups with CDI at increased recur-
rence risk, from the German payer perspective. Based on 
a willingness-to-pay threshold of €50,000, fidaxomicin 
was found to be dominant (less costly and more effective) 
in patients with cancer and cost-effective in all of the other 
subgroups.
Despite the substantially higher acquisition cost of 
fidaxomicin compared with vancomycin, this is offset by 
the reduction in costs associated with treating recurrence 
and by the reduced hospitalization costs; therefore, fidax-
omicin is cost-saving in the cancer subgroup and associated 
Table 3  Budget impact (per patient) of the first-line treatment of 
CDI with fidaxomicin vs. vancomycin in patient subgroups
CDI Clostridium difficile infection










≥1 recurrence 9016 8555 461




≥65 years 9008 8547 461




Table 4  Hospitalization costs (per patient) of the first-line treatment 
of CDI with fidaxomicin vs. vancomycin in patient subgroups











≥1 recurrence 7081 8429 −1347




≥65 years 7074 8399 −1325
Cancer 6853 9291 −2438
Renal impairment7792 9367 −1575
Table 5  Economic and patient impact of less recurrence with fidax-
omicin, compared with vancomycin in 100 patients treated with 
fidaxomicin vs. vancomycin
CDI Clostridium difficile infection
Subgroups Reduction in the cost 
of treating recurrence 
with fidaxomicin vs. 
vancomycin (€)
Reduction in the 
number of recurrences 
with fidaxomicin vs. 
vancomycin
≥1 recurrence −94,129 −22.49




≥65 years −103,349 −21.68
Cancer −148,142 −23.06
Renal impairment −150,068 −26.78
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with incremental costs of €291 to €461 per patient in the 
other groups.
The deterministic sensitivity analyses showed that the 
key drivers of cost-effectiveness are recurrence, clinical 
cure rates, and CDI-attributable mortality. This type of sen-
sitivity analysis has some limitations, including an evalu-
ation of the impact of only a small number of parameters, 
and the lack of account for the potential interdependence 
between parameters. However, it is useful for assessing the 
key drivers of cost-effectiveness. The findings of the cur-
rent deterministic analyses reflect the results of phase III 
trials, showing that fidaxomicin was associated with lower 
rates of recurrence and higher rates of sustained response/
global cure rates than vancomycin in patients ≥65 years, 
those with a previous episode of CDI [3, 17], those with 
severe CDI at baseline [3, 17], those taking concomitant 
antibiotics [7], or with renal impairment [13] or cancer 
[12]. Differences were statistically significant (p ≤ 0.05) 
for both variables for those with cancer or taking concomi-
tant antibiotics [12, 13], for recurrence in those ≥65 years 
or with severe CDI in one study [3] and with chronic 
kidney disease stage 2 in another [13] and for sustained 
response in those with severe CDI at baseline [17]. Moreo-
ver, analysis of the combined data for these trials showed 
that overall, fidaxomicin reduced persistent diarrhea, recur-
rence, or death by 40 % compared with vancomycin [30]. 
These effects of fidaxomicin are likely to reduce hospital 
readmission rates; indeed, in the current budget impact 
analysis, hospitalization costs were lower with fidaxomicin 
than vancomycin in all subgroups. A recent analysis of a 
patient discharge database showed that reductions in hos-
pital-onset CDI and readmission of patients with an index 
CDI can provide tremendous cost savings to hospitals [31]. 
A reduced recurrence rate is likely in turn to reduce hospi-
tal readmission rates and the overall number of bed-days 
with fidoxamicin. Hospital bed-days have been reported 
to account for up to 94 % of the cost of CDAD treatment 
[32]. Furthermore, a recent real-world study showed that 
the overall readmission rate of fidaxomicin-treated patients 
was low (6.9 %) [33].
Cost-effectiveness in CDI treatment is important in the 
German setting as shown by a recent German hospital 
study that found CDAD generates a yearly overall cost of 
€464 million to the healthcare system [21]. In this study, 
recurring cases were associated with higher costs (€20,755 
per case) than those with CDAD as a primary diagno-
sis (€4132) [21]. Recurring cases were associated with 
higher costs in a recent cost-of-illness analysis assessing 
the impact of CDAD and CDAD recurrence in the German 
health system [16]. In that analysis, the mean overall direct 
treatment costs in the recurrence group were €73,898 such 
that additional direct costs related to CDAD were €59,367 
in the recurrence group compared with matched non-
CDAD control patients [16].
Our analysis complements previous cost-effectiveness 
studies with fidaxomicin. A study from the perspective of 
Scottish public healthcare providers showed that fidax-
omicin was cost-effective in patients with severe CDI and 
in those with a first CDI recurrence [18]. A US study from 
the third-party payer perspective found that fidaxomicin 
may be a more cost-effective option for the treatment of 
CDIs compared with vancomycin under most scenarios 
tested [34]. In addition, a recent cost-utility analysis from 
an Irish Health Service Executive perspective showed that 
fidaxomicin was dominant to vancomycin or metronida-
zole for the treatment of CDI [19]. Finally, a cost-utility 
study from the Spanish National Health Service perspective 
showed that the treatment of CDI with fidaxomicin would 
be cost-saving and lead to improved quality of life when 
compared with vancomycin in patients with cancer, renal 
impairment, or treated with concomitant antibiotics [35].
Limitations of the model include the need to make 
assumptions to address uncertainties. In the current model, 
the 6.5 % mortality rate was based on 30-day all-cause 
mortality from phase III trials. However, this is consist-
ent with literature estimates for CDI-attributable mortal-
ity (5.7–6.9 %) [22–24]. Furthermore, in view of its more 
favorable sustained cure and recurrence rates, this is likely 
to be a conservative approach regarding the benefits of 
fidaxomicin vs. vancomycin. Indeed, it has been shown that 
recurrent CDI is associated with significantly higher mor-
tality rates [36]. The model also applied the same recur-
rence risk to first and subsequent recurrence—again, this 
is a conservative assumption as in practice, the risk of a 
second recurrence is likely to be higher [37]. It was also 
assumed that all cases of CDI were treated on a general 
ward in hospital. In a real-world setting, it is likely that 
some patients with CDI will be treated in intensive care or 
an infectious diseases unit, while others may be treated in 
the outpatient setting. The assumptions for hospitalization 
costs and lengths of stay used in the model (€348/day on 
a general ward and 14.6 days) appear very conservative 
since a recent German hospital cost-of-illness study on the 
economic burden of CDAD [16] found that patients with 
recurrence spent 62 additional days in hospital (compared 
with those without recurrence), resulting in excess over-
all direct treatment costs of €55,438 per patient. Finally, 
another limitation of the model is that metronidazole was 
not included as a treatment option. This was because there 
are no direct comparative studies between fidaxomicin and 
metronidazole, although the results from a recent network 
meta-analysis indicate that fidaxomicin is associated with 
a significantly lower recurrence rate in CDI than metroni-
dazole [38].
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Conclusion
Using a semi-Markov decision analytic model, our analy-
sis in a German hospital setting showed that in patient 
subgroups with CDI at increased recurrence risk, first-
line fidaxomicin was cost-effective vs. vancomycin, and 
less costly and more effective in patients with cancer 
over a 1-year time horizon. This is despite the higher 
acquisition cost of fidaxomicin and is a result of sav-
ings associated with lower hospital readmissions as more 
recurrences are prevented with fidaxomicin. These results 
are highly relevant given the emphasis on reducing hos-
pital admissions and overall length of stay in European 
healthcare systems.
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